Heart Failure, Systolic
Conditions
Brief summary
The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Detailed description
Prior studies have demonstrated an association between the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors for diabetic patients and reductions in composite primary outcomes of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke, as well as reductions in heart failure among patients with diabetes. The 2019 DAPA-HF trial studied whether the addition of the SCLT-2 inhibitor dapagliglozin could benefit patients with heart failure with reduced ejection fraction (HFrEF), either with or without diabetes. Results indicated that that SGLT-2 inhibitors resulted in 4.9% absolute reduction in the cardiovascular death or worsening heart failure and a 2.3% absolute reduction in all-cause mortality in patients with and without diabetes. Dapagliflozin is FDA approved to reduce the risk of cardiovascular death or hospitalization in patients with HFrEF with or without Type 2 diabtes. The mechanisms of cardiovascular benefit remain unclear, however it is likely to be driven by a reduction in heart failure death given that rates of myocardial infarction were similar between treatment arms. The CardioMEMS® system is an implantable device that can measure pulmonary artery systolic, diastolic and mean pressure on a daily basis. It has been shown convincingly that monitoring the MEMS device results in reduced pulmonary pressures and in turn a reduction in heart failure hospitalizations. The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Interventions
DRUGDapagliflozin
The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
DEVICECardioMEMS
The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Sponsors
Scripps Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of HFrEF and existing CardioMEMs in place 2. Patients who have historically been compliant with CardioMEMS followup 3. Ejection fraction \< or = to 40% 4. New York Heart Association (NYHA) class II-IV heart failure 5. Able to read and write in English
Exclusion criteria
1\. creatinine clearance less than or equal to 45 2. History of renal transplant 3. systolic blood pressure less than 85 on time of initiation of drug 4. intolerance/allergy to farxiga 5. pregnant patients or those who are planning to become pregnant during the study period 6. unable to read and write in English 7. acutely hospitalized patients or those who were hospitalized in the past 30 days 8. history of noncompliance with CardioMEMS followup 9. History of frequent mycotic urinary tract infections 10. History of organ transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of Dapagliflozin on pulmonary diastolic pressure from baseline to 12 weeks of therapy Secondary End Points | 12 weeka | PA diastolic pressure change |
| Compare the change in PA pressures, systolic and mean, from baseline to 12 weeks. | 12 weeks | PA pressure changes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe the change in NT-ProBNP from baseline to 12 weeks | 12 weeks | NTproBNP change |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in renal function estimated GFR from baseline to 12 weeks | 12 weeks | renal function |
| Compare total diuretic dose from baseline to 12 weeks. | 12 weeks | diuretic dose |
| Change in weight baseline to 12 weeks | 12 weeks | weight |
| Determine the change in 6 min walk distance from baseline to 12 weeks | 12 weeks | 6 MWT |
| Compare the change in KCCQ from baseline to 12 weeks. | 12 weeks | KCCQ |
Countries
United States
Outcome results
None listed